Alzamend Neuro, Inc. (ALZN)
Total Valuation
Alzamend Neuro has a market cap or net worth of $85.86 million. The enterprise value is $74.07 million.
| Market Cap | 85.86M |
| Enterprise Value | 74.07M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Alzamend Neuro has 93.02 million shares outstanding. The number of shares has increased by 30.31% in one year.
| Shares Outstanding | 93.02M |
| Shares Change (YoY) | +30.31% |
| Shares Change (QoQ) | +0.76% |
| Owned by Insiders (%) | 48.58% |
| Owned by Institutions (%) | 3.64% |
| Float | 50.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 7.18 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | 26.62 |
| Quick Ratio | 25.25 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | 0.00 |
Financial Efficiency
Return on equity (ROE) is -92.10%, which is considered low. The company has a ROIC of -8,505.10%.
| Return on Equity (ROE) | -92.10% |
| Return on Assets (ROA) | -83.60% |
| Return on Capital (ROIC) | -8,505.10% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.25M |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (1Y) | n/a |
| Total Price Change | -81.80% |
| 50-Day Moving Average | 1.04 |
| 200-Day Moving Average | 1.59 |
| Average Volume (30 Days) | 1,326,103 |
Short Selling Information
The latest short interest is 1.60 million, so 1.72% of the outstanding shares have been sold short.
| Short Interest | 1.60M |
| Short % of Shares Out | 1.72% |
| Short % of Float | 3.18% |
| Short Ratio (days to cover) | 1.10 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -9.67M |
| Net Income | -9.75M |
| EBITDA | -9.67M |
| EBIT | -9.67M |
| Earnings Per Share (EPS) | -$0.11 |
Balance Sheet
The company has $11.79 million in cash and no debt, giving a net cash position of $11.79 million or $0.13 per share.
| Cash & Cash Equivalents | 11.79M |
| Total Debt | 0 |
| Net Cash | 11.79M |
| Net Cash Per Share | $0.13 |
| Book Value | 11.96M |
| Book Value Per Share | 0.13 |
| Working Capital | 11.96M |
Cash Flow
| Operating Cash Flow | -6.31M |
| Capital Expenditures | n/a |
| Free Cash Flow | -6.31M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Alzamend Neuro does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -11.36% |
| FCF Yield | -7.35% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.31% |
| Shareholder Yield | -30.31% |
Analyst Forecast
The average price target for Alzamend Neuro is $11.48, which is 1,143.77% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.48 |
| Price Target Difference | 1,143.77% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |